Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$14.8MCash, Pro Forma
21.3mo Cash Runway
Follow SCNI by emailGet an email when SCNI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SCNI, unsubscribe in one click. Privacy
📣 What SCNI Says Is Next
in January 2027 · “It provides greater visibility into our manufacturing workload for 2027 and combines development and IND-enabling activities underway in 2026 with a clinical manufacturing program planned to begin in January 2027.” “Our priority is to translate these commitments into revenue, increased facility utilization and stronger operating performance, while continuing to aggressively grow the business.”
Company press release, Oct 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Listing Effective November 19, 2026, the ADS ratio will change from one ADS representing 40,000 ordinary shares to one ADS representing 160,000 ordinary shares, equivalent to a one-for-four reverse split of the ADSs. Form 6-K · SEC filing
Nov 10, 2026 ·
Financing Prospectus for resale by selling shareholders of up to 7,587,543 ADSs issuable on exercise of pre-funded warrants, Series A-1 warrants and placement agent warrants from an October 13, 2026 private placement. The company will not receive offering proceeds, only warrant exercise cash if exercised. Form 424B3 · SEC filing
Nov 9, 2026 ·
Earnings Revenue rose 167% to $2.8 million for the nine months ended September 30, 2026, but gross loss widened to $2.97 million. Net loss narrowed to $0.39 million because of a $6.40 million noncash bargain purchase gain. The company signed a U.S. CDMO agreement with about $5.1 million in committed base fees. Form 6-K · SEC filing · Press release
Oct 28, 2026 ·
Financing Scinai registered for resale up to 7,587,543 ADSs held by selling shareholders, mostly underlying pre-funded warrants and Series A-1 warrants issued in an October 13, 2026 private placement. The company will not receive proceeds from resales. Shares last traded at $0.53 per ADS on Nasdaq. Form F-3 · SEC filing
Oct 20, 2026 ·
Deal CEO letter says a new CDMO agreement includes about $5.1 million in committed base service fees and Committed Customer Orders reached about $8.1 million. Financing raised about $5.3 million in combined net proceeds, and runway is estimated to late 2027. Form 6-K · SEC filing · Press release
Oct 16, 2026 ·
Financing Scinai closed a $4.0 million gross private placement and warrant inducement, before placement agent fees, selling 2,458,334 ADSs plus Series A-1 Warrants for up to 3,687,501 ADSs. Existing warrants for 879,194 ADSs were exercised at $1.20 each. The company estimates an operating runway to late 2027. Form 6-K · SEC filing · Press release
Oct 15, 2026 ·
Financing Scinai agreed to sell 2,458,334 ADSs (or pre-funded warrants) at $1.20 per ADS with Series A-1 warrants for up to 3,687,501 ADSs at $1.20, plus a warrant inducement for 879,194 ADSs, for expected gross proceeds of about $4.0 million. Form 6-K · SEC filing · Press release
Oct 13, 2026 ·
Deal Scinai signed a development and clinical manufacturing agreement worth about $5.1 million in committed base service fees with a U.S.-based, Nasdaq-listed biopharma company. Committed Customer Orders reached about $7.6 million, up roughly 300% from $1.9 million at year-end 2025. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SCNI had $10.8M in cash and short-term investments on its Mar 31, 2023 balance sheet.
Including the cash events since then, it holds about $14.8M pro forma, before operating spending after that date:
Closed private placement, announced Oct 16, 2026 (gross proceeds): $4M · 6-K
It burns about $2.1M/quarter from operations, an estimated runway of 21.3 months from Mar 31, 2023 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:8 · Low
Cash runway 21 months (pro forma for cash events since the balance sheet) +8
Share count 13,872,899,584 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SCNI picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCNI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.